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Abstract 
Introduction and objectives. To estimate the percentage of heart failure patients in Spain that received the European 
Society of Cardiology recommended treatments, and in those that did not, to determine the reasons why. 
Methods. The study included 2834 consecutive ambulatory patients with heart failure from 27 Spanish hospitals. We 
recorded general information, the treatment indicated, and the reasons why it was not prescribed in some cases. In 
patients who met the criteria to receive a certain drug, true undertreatment was defined as the percentage of patients 
who, without justification, did not receive the drug. 
Results. In total, 92.6% of ambulatory patients with low ejection fraction received angiotensin converting enzyme 
inhibitors or angiotensin receptor blockers, 93.3% beta-blockers, and 74.5% mineralocorticoid receptor antagonists. 
The true undertreatment rates were 3.4%, 1.8%, and 19.0%, respectively. Target doses were reached in 16.2% of 
patients receiving angiotensin converting enzyme inhibitors, 23.3% of those with angiotensin receptor blockers, 
13.2% of those prescribed beta-blockers, and 23.5% of those with mineralocorticoid receptor antagonists. Among 
patients who could benefit from ivabradine, 29.1% received this drug. In total, 36% of patients met the criteria for 
defibrillator implantation and 90% of them had received the device or were scheduled for implantation, whereas 
19.6% fulfilled the criteria for resynchronization therapy and 88.0% already had or would soon have the device. In 
patients who met the criteria, but did not undergo device implantation, the reasons were not cost-related. 
Conclusions. When justified reasons for not administering heart failure drugs were taken into account, adherence to 
the guideline recommendations was excellent. Exclusive use of the percentage of treated patients is a poor indicator 
of the quality of healthcare in heart failure. Measures should be taken to improve the attainment of optimal dosing in 
each patient. 
Resumen 
Introducción y objetivos. Estimar la proporción de pacientes con insuficiencia cardiaca atendidos en España que 
reciben los tratamientos recomendados por la Sociedad Europea de Cardiología y razones de que no los reciban, en su 
caso. 
Métodos. Se incluyó a 2.834 pacientes ambulatorios consecutivos con insuficiencia cardiaca de 27 hospitales 
españoles. Se recogió información general, tratamiento indicado y causas de que no lo recibiera, en su caso. De los 
pacientes que cumplen criterios para recibir tratamiento, infratratamiento real es la proporción que, sin justificación, 
no lo recibe. 
Resultados. El 92,6% de los pacientes ambulatorios con fracción de eyección reducida recibieron inhibidores de la 
enzima de conversión de la angiotensina o antagonistas del receptor de la angiotensina II; el 93,3%, bloqueadores 
beta y el 74,5%, antagonistas del receptor mineralocorticoideo. El infratratamiento real es del 3,4, el 1,8 y el 19,0% 
respectivamente. Alcanzan dosis objetivo de inhibidores de la enzima de conversión de la angiotensina el 16,2% de 
los pacientes; de antagonistas de los receptores de la angiotensina II, el 23,3%; de bloqueadores beta, el 13,2% y de 
antagonistas del receptor mineralocorticoideo, el 23,5%. El 29,1% de los pacientes que podrían beneficiarse de 
ivabradina la reciben; el 36% cumple criterios para implantar desfibrilador; de ellos, el 90% lo tienen ya implantado o 
programado; las cifras correspondientes en resincronización son el 19,6 y el 88,0%; el porcentaje restante no se debe 
a causas económicas. 
Conclusiones. Considerando razones justificadas para no administrar fármacos a estos pacientes, el cumplimiento de 
las guías es excelente. Utilizar solo la proporción de pacientes tratados es un mal indicador de calidad de la asistencia 
en insuficiencia cardiaca. Es necesario introducir medidas que mejoren el logro de la dosis óptima para cada paciente. 
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INTRODUCTION 
Heart failure (HF) is a persistent health problem that places a significant burden on the health system 
and society in general and is anticipated to increase in the future.
1
 
 
Certain treatments for this condition, some of which have been recently implemented,
2,3
 have proven 
effective for reducing HF events, particularly those leading to rehospitalization. Nonetheless, the 
incorporation of these advances in clinical practice tends to be slow. As a result, several studies 
investigating HF
4,5
 and other conditions
6,7
 have reported a discrepancy between the accepted approaches 
published in clinical practice guidelines and the activity seen in regular clinical practice. With regard to 
HF, the gap between recommendations and what is done in clinical practice is much smaller now than in 
previous years, after justified reasons for not administering a recommended therapy have been taken into 
account.
8
 
 
The European Society of Cardiology (ESC) has developed an HF registry, the ESC Heart Failure 
Long-Term Registry,
8
 to which Spain makes a prominent contribution, with 28.4% of all patients 
included in Europe (3536 of 12 440). This registry provides a good opportunity to evaluate whether the 
treatment of hospitalized and ambulatory HF patients in Spain is performed in accordance with the 
European recommendations.
3,9
 
 
Thus, the primary aim of this study was to estimate the percentage of HF patients attended in Spain 
who received the treatments recommended in the 2012 ESC guidelines, and, in those who did not, to 
determine the reasons why. 
METHODS 
Study Design and Centers 
The ESC Heart Failure Long-Term Registry registry is a prospective, multicenter observational study 
performed in HF patients attending 211 cardiology centers in 21 ESC member countries in Europe and 
the Mediterranean area, including Spain. 
 
The aim of ESC Heart Failure Long-Term Registry is to describe the clinical epidemiology of 
ambulatory and hospitalized patients with HF and to determine the diagnostic and therapeutic processes 
(including the organization of programs for HF management) applied in these patients over Europe as a 
whole and in the Mediterranean countries. 
 
The registry was designed within the EORP (EURObservational Research Program) of the European 
Heart House of the ESC, and is coordinated by the EORP, which provides support to the related 
committees, national coordinators, and participating centers.
10
 Data are entered in a common electronic 
database that limits inconsistencies and errors and provides online help for key variables. Each center has 
access to its own data and each national coordinator has access to the data from all participating centers in 
that country. 
 
The number of centers participating in each country was determined according to the size of the 
population. Attempts were made to have a balanced geographical representation while taking into account 
the differing care levels of the cardiology departments treating HF patients. Centers were selected 
(Appendix) through each country's national cardiology society and HF section, as established for EORP 
registries and surveys.
11
 
  
Patients 
On 1 day of the week over the 12 months of the inclusion period (April 2012-April 2013), each center 
included all HF patients older than 18 years attending the outpatient clinic and all those hospitalized on 
the same day for acute HF (either de novo HF or decompensation of a previous acute HF) with an 
intravenous therapy requirement (inotropic agents, vasodilators, or diuretics). Data collection was 
performed according to the criteria of the principal investigator of each center, and was usually carried 
out by personnel with no clinical activity assigned to the project. 
 
A follow-up visit was scheduled at 1 year, either by personal interview or telephone contact (the data 
are not presented in this article). The present report includes only the ambulatory patients (chronic HF) 
recorded in the registry. In this population, the most robust recommendations in the 2012 ESC guidelines 
are for patients with HF and low ejection fraction (EF). An analysis was performed to determine whether 
these patients received the treatments recommended in the guidelines, specifically angiotensin-converting 
enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), mineralocorticoid receptor antagonists 
(MRA), and ivabradine. Furthermore, the investigators recorded the dose of each drug given, and whether 
the dose used was the target dose established in clinical trials. In patients who did not receive these drugs 
and in those who did not attain the target dose, the reasons for these circumstances were analyzed. 
 
The ESC Heart Failure Long-Term Registry has a quality assurance program that includes audits in 
around 10% of the participating centers, selected randomly. Two Spanish centers were audited in 2013. 
 
The study was approved by the ethics committee of each center, and all patients gave informed 
consent for their inclusion. 
Statistical Analysis 
The results for continuous variables are expressed as the median [first and third quartile] and the 
results for categorical variables as percentages. The analyses were performed centrally by support staff of 
the EORP Department of the European Heart House using SAS software (SAS Institute, Inc.; Cary, North 
Carolina, United States). 
RESULTS 
The results presented correspond to 2834 ambulatory patients (chronic HF group) recorded from 
Spanish centers. The results from the group of hospitalized patients (n = 702 in Spain) are not included 
because the guideline recommendations for this population are based on a low level of evidence. The 27 
hospitals participating in Spain included centers providing different levels of care: 19 centers offered the 
full range of cardiologic services, including interventional procedures (catheterization, cardiac 
resynchronization, defibrillator implantation) and cardiac surgery (in Spain, most of these centers also 
perform heart transplants); 4 centers provided interventional procedures, but not cardiac surgery; and 4 
centers had cardiology units but did not carry out cardiac interventional procedures or cardiac surgery. 
General Characteristics 
The patients’ characteristics are summarized in Table 1. Patients included in the study were relatively 
young (half younger than 65 years), predominantly male, and only 1 of 4 patients had preserved EF (> 
45%). 
  
Table 1. Baseline Patient Characteristics 
 
CHF* 
  
Patients, No. 2834 
Age, years 65 [56-73] 
Women 28.5 
BMI 28 [25-31] 
SBP, mmHg 120 [110-134] 
SBP ≤ 110 mmHg 32.7 
HR, bpm 70 [60-76] 
HR ≥ 70, bpm 50.2 
EF, % 35 [28-46] 
EF > 45% 25.4 
NYHA functional class III-IV 17.0 
Pulmonary or peripheral congestion 51.7 
Third heart sound 2.9 
Peripheral/cold hypoperfusion 2.0 
Mitral regurgitation 13.3 
Aortic stenosis 3.1 
Previous hospitalization 51.4 
HF diagnosis >12 months 63.4 
Ischemic cause 38.5 
Atrial fibrillation 33.6 
Diabetes mellitus 35.1 
Peripheral arterial disease 12.1 
Hypertension 55.9 
COPD 14.8 
Sleep apnea 8.3 
Stroke/TIA 8.3 
Renal dysfunction 15.7 
Hepatic dysfunction 2.5 
Depression 9.0 
Pacemaker 6.0 
  
 
BMI, body mass index; CHF, chronic heart failure; COPD, chronic 
obstructive pulmonary disease; EF, ejection fraction; HF, heart 
failure; HR, heart rate; NYHA: New York Heart Association 
functional class; SBP, systolic blood pressure; TIA, transient 
ischemic attack. 
Unless otherwise indicated, the values express the percentage or the 
median [first and third quartile]. 
* Ambulatory patients. 
Pharmacological Treatment in Ambulatory Patients 
Angiotensin converting enzime inhibitors/ARB were prescribed in 86.8% of ambulatory patients, 
beta-blockers (BB) in 88.7%, and MRA in 63.8% (Table 2). In patients with low EF (EF ≤ 40% or ≤ 35% 
for MRA), which is the profile of patients deemed suitable to receive these treatments in the 2012 ESC 
guidelines, ACEI/ARB were prescribed in 92.6%, BB in 93.3%, and MRA in 74.5%. Furthermore, 65.4% 
(795/1.216) of patients with EF ≤ 35% were prescribed all 3 types of drugs (ACEI/ARB, BB, and MRA). 
  
Table 2. Pharmacological Treatment in Ambulatory Patients with Heart Failure 
Treatments 
Total population  
(n = 2409) 
Low EFa  
(≤ 40%) (n = 1526) 
Preserved EFa  
(> 40%) (n = 883) 
    
ACEI/ARB 86.8 92.6 76.8 
ACEI 58.7 64.6 48.5 
Ramiprilb 40.6 42.9 35.3 
Enalaprilb 51.4 49.1 56.5 
Perindoprilb 1.1 0.4 2.8 
Beta-blockers 88.7 93.3 80.9 
Carvedilolb 52.3 55.0 46.9 
Bisoprololb 37.4 36.3 39.6 
Metoprololb 1.0 0.9 1.3 
ARB 28.9 29.1 28.5 
Candesartanb 32.0 35.1 26.6 
Losartanb 30.5 31.1 29.4 
Valsartanb 23.6 22.8 25.0 
MRAa 63.8 74.5 52.9 
Spironolactoneb 50.0 47.6 53.4 
Eplerenoneb 49.6 52.2 45.8 
Canrenoneb 0.1 0.1 0.0 
Diuretics 78.5 83.3 70.1 
Digitalis 20.3 22.0 17.3 
Statins 62.4 66.7 54.8 
Antiplatelet agents 43.3 48.6 34.3 
Oral anticoagulants 42.6 41.9 43.7 
Amiodarone 10.2 11.3 8.3 
Ivabradinea 14.5 19.7 9.2 
Nitrates 15.7 16.8 13.6 
Calcium channel blockers 8.8 5.6 14.5 
    
 
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; MRA, mineralocorticoid receptor 
antagonists; EF, ejection fraction. Data are expressed as percentage. 
a In the case of mineralocorticoid receptor antagonists and ivabradine, the low and preserved ejection fraction groups are ejection 
fraction ≤ 35% (n = 1216) and ejection fraction > 35% (n = 1193). 
b Percentage of the total taking any of the drugs of the corresponding group. 
As to ivabradine, 70.9% of ambulatory patients (249/351) with sinus rhythm, EF ≤ 35%, and heart rate 
≥ 70 bpm did not receive ivabradine, and in this same subgroup, only 21.6% of patients (76/351) were 
prescribed all 4 types of drugs (ACEI/ARB, BB, MRA, and ivabradine). 
 
In a large proportion of the patients not prescribed the treatments recommended in the guidelines 
(ACEI/ARB, BB, and MRA), there was a justification for doing so. The distribution of ambulatory 
patients with low EF (≤ 40%) according to whether or not they received each of the 3 main drug classes is 
shown in Figure 1, and in those who did not receive these drugs, the reasons for not doing so are listed. In 
patients who were not prescribed each of the treatments, the true underprescription rates—that is, the 
percentage of patients not prescribed a treatment and with no recorded justification—were 3.4% for 
ACEI/ARB, 1.8% for BB, and 19.0% for MRA. 
 
  
 
 
 
Figure 1. Reason why recommended treatments were not used in patients (n = 1526) with low ejection fraction (≤ 40%). ARB, 
angiotensin receptor blockers; ACEI, angiotensin converting enzyme inhibitors; MRA, mineralocorticoid receptor antagonists; 
COPD, chronic obstructive pulmonary disease; HF, heart failure. 
  
Only a small percentage of ambulatory patients with a low EF reached the target doses reported in 
clinical trials using these drugs: 16.2% of those receiving ACEI, 23.3% of those with ARB, 13.2% of 
patients with BB, and 23.5% of patients receiving MRA (Table 3). There was often a clinical reason 
indicating that the dose prescribed was optimal for the patient, but in at least 1 of 4 patients (1 of 2 in the 
case of MRA), no justification was recorded. 
Table 3. Attainment of the Target Dose in Recommended Treatments for Ambulatory Patients With Low Ejection Fraction 
 
Achieved target 
dose 
Did not achieve 
target dose 
Reason for not achieving target dose 
     
ACEI (977 patients) 158 (16.2) 819 (83.8) Still in drug titration phase 248 (30.3) 
   
Symptomatic hypotension 254 (31.0) 
   
Worsening of renal function 48 (5.9) 
   
Hyperkalemia 37 (4.5) 
   
Cough 3 (0.4) 
   
Angioedema 1 (0.1) 
   
Others/unknown 228 (27.8) 
ARB (395 patients) 92 (23.3) 303 (76.7) Still in drug titration phase 91 (30.0) 
   
Symptomatic hypotension 97 (32.0) 
   
Worsening of renal function 27 (8.9) 
   
Hyperkalemia 8 (2.6) 
   
Angioedema 2 (0.7) 
   
Others/unknown 78 (25.7) 
Beta-blockers (1413 
patients) 
186 (13.2) 1227 (86.8) Still in drug titration phase 425 (34.6) 
   
Symptomatic hypotension 240 (19.6) 
   
Bradyarrhythmia 111 (9.0) 
   
Worsening of HF 39 (3.2) 
   
Bronchospasm 33 (2.7) 
   
Worsening of PAD 22 (1.8) 
   
Sexual dysfunction 7 (0.6) 
   
Others/unknown 350 (28.5) 
MRA (905 patients) 213 (23.5) 692 (76.5) Still in drug titration phase 185 (26.7) 
   
Hyperkalemia 72 (10.4) 
   
Worsening of sexual dysfunction 84 (12.1) 
   
Gynecomastia 4 (0.6) 
   
Others/unknown 347 (50.1) 
     
 
ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; HF, heart failure; MRA, mineralocorticoid 
receptor antagonists; PAD, peripheral arterial disease. Data are expressed as No. (%). 
Device Use in Ambulatory Patients 
Figure 2 shows the distribution of ambulatory patients according to whether or not they had an 
indication for defibrillator implantation or cardiac resynchronization therapy, whether they already had a 
device, and the reasons why they did not have a device despite having an indication for one. In total, 
64.0% of patients did not fulfill the guidelines’ criteria for defibrillator implantation and 80.4% did not 
meet the criteria for cardiac resynchronization therapy. Among patients with criteria for defibrillation, 
78% (788 of 1016) already had defibrillators and an additional 12% were in the planning process for 
defibrillator implantation. In patients with an indication for resynchronization therapy, 74% (406 of 549) 
already had a pacemaker and 14% (76 of 549) were in the planning process. In patients who met the 
criteria but were not considered for device implantation (10% for defibrillators and 12% for 
resynchronization), the main reason for this circumstance was uncertainty about the indication.  
 
 
 
Figure 2. Automated defibrillator implantation rates, cardiac resynchronization therapy rates, and reasons why ambulatory patients 
did not receive these treatments (n = 2834). 
DISCUSSION 
This study brings to light the focus of HF treatment on meeting the requirements of individual 
patients. Furthermore, it shows that simple calculation of the percentage of treated patients may not be an 
appropriate measure to indicate the quality of the healthcare provided in a specific condition. Compared 
with previous reports, this study has the added value of careful, comprehensive collection of the 
treatments and doses administered in the population examined, as well as the reasons why indicated drugs 
were not prescribed or the doses given did not reach the targets defined in clinical studies. A previous 
estimation from the European Heart Failure Pilot Survey, ESC-HF Pilot,
11
 which described only the 
number of patients treated, reported administration of ACEI/ARB, BB, and MRA in 88.5%, 86.7%, and 
43.7% of patients, respectively. In contrast, when justified reasons for not prescribing a certain treatment 
were taken into account, we found that the true problem of undertreatment in Spain is practically 
inconsequential with regard to ACEI/ARB and BB (3.4% and 1.8%), whereas there is still a wide margin 
for improvement in MRA prescription (true undertreatment in 19.0%). 
 
Another observation highlighted by this study has important implications for clinical practice. We 
found that compliance with the guidelines regarding treatment indications has improved considerably 
compared with the situation 10 years ago. At that time, Spain showed the lowest use of BB and ACEI 
(around 10% and 40%, respectively) among all the participating European countries,
12
 whereas the 
current prescription of recommended HF treatments is excellent (with the possible exception of MRA). 
Nonetheless, this improvement was not seen in attainment of the doses defined in clinical trials, as most 
patients did not receive the target doses of the treatments indicated. In a large percentage of these patients, 
there was a sound reason for this situation: dosing was in the adjustment phase or there were toxicity 
symptoms indicating that the maximum dose tolerated had been reached. Therefore, many of these 
patients were actually receiving their optimal dose; that is, the maximum “possible dose” even though it 
may not have been the “target dose”. Despite these findings, in 1 of every 4 patients (1 of 2 in the case of 
MRA), no reason was given for the lower doses. These percentages should be considered the worst-case 
scenario according to the available information. Even in a high-quality registry carried out meticulously, 
the reasons for lower dosing might not be available to the person collecting this information in each 
center because of the nature of the HF treatment process (performed by several professionals over time, 
working in different settings). Another factor that could have made a substantial contribution to the gap 
between our results and the target doses is the difficulty of establishing rigorous programs for dose 
titration of HF drugs. Dose adjustment implies numerous visits and laboratory analyses to carefully tailor 
the treatment to the patient's requirements. It would be of particular value if our patients could be attended 
when and where they need these visits, and not simply according to the availability of regular care, which 
is necessarily restricted. This is a limitation that hinders proper use of our therapeutic resources and it 
underscores the need to establish integrated programs that go beyond the hospital setting and include 
health professionals of several types (eg, specialized physicians in the hospital and community, 
specialized nurses).
13
 
  
This study has an advantage over other registries in Spain, some of them quite recent,
4,14,15
 in that it 
allows direct comparison with other data in the European registry, of which it forms a part. All 
contributors to this cornerstone project of the ESC use identical methods. Furthermore, it is an active 
registry that continues to include patients and their follow-up. The situation regarding the true 
undertreatment rates in Spain is virtually the same as that reported for the overall European study
8
 
(including Spanish centers). However, although the percentage of patients reaching the target doses 
established in clinical trials is rather low throughout Europe, it is slightly lower in Spain.
3
 
 
As to the more recently available HF drugs such as ivabradine, it seems that their incorporation has 
been faster in Spain than in Europe as a whole, in both patients with low EF (19.7% vs 10.5%) and in the 
overall cohort of ambulatory patients (14.5% vs 8.5%).
8
 Of note, however, in the subanalysis of 
ivabradine use in Spain, low EF was defined as ≤ 35%, whereas in the overall European analysis it was ≤ 
45%.
8
 In a Spanish study in ambulatory patients conducted approximately 1 year before these results, 
only 7.2% of patients received this drug.
16
 Despite the current improvement, the percentage of patients in 
Spain who meet the criteria for ivabradine treatment but are not prescribed this drug remains high: only 
29.1% of ambulatory patients with sinus rhythm, EF ≤ 35%, and heart rate ≥ 70 bpm received this 
medication, again reflecting the delay between demonstration of the benefits of a specific intervention and 
its incorporation into clinical practice. This aspect should be reassessed in the future. In contrast to other 
drugs, ivabradine was incorporated for the first time in the 2012 guidelines, which were published at the 
same time as the start of data collection for the registry in Spain. Information on adherence to the 
guidelines for this medication throughout Europe has not yet been published, which prevents direct 
comparison in the subgroup of patients in whom the guidelines recommend its use. 
 
As regards device use, it seems that the reasons why patients with indications for these devices did not 
receive them are not exclusively economic, despite the economic crisis. It is possible that physicians 
themselves may be managing resource use while keeping in mind the existing economic difficulties, but 
this would have very different implications than if devices were not being implanted for purely economic 
reasons. 
Limitations 
Some of the potential limitations of this study have been mentioned in other sections of the discussion. 
The main limitation is that with the available data it is impossible to assure that case recording was 
complete in all the participating Spanish centers. Some hospitals included fewer patients than others of 
the same size and care level, although this occurred in very few centers. Huge efforts have been made to 
simplify the protocol and improve the possibility of including all consecutive patients seen on the registry 
days. Although complete recording has not been confirmed in all centers, the audits performed in 2 
Spanish hospitals indicated good compliance with the study protocol (unpublished data, personal report 
from the EORP staff). As a reflection that case recording was good in our centers, Spain was the country 
with the largest number of patients included in the registry among all participants. Another possible 
limitation lies in the procedure for selecting participating centers, which was not done randomly. Among 
the centers interested in participating, a larger number of tertiary-level hospitals were included than those 
recommended by the protocol,
11
 which resulted in the participation of fewer lower-level centers. This 
reflects the organization of HF care in Spain: lower-level centers may not have HF units, and care for 
these patients is often delegated to internal medicine specialists rather than cardiologists, who mainly 
perform complementary testing. We believe that the final list reflects the varying profile of Spanish 
centers in which cardiologists are responsible for the care of HF patients and that it is geographically 
representative, in case this factor might be important in the estimations made. The design of the database 
and the software for data entry, which, for example, had online information about recommended dosing, 
guarantee high-quality data and enable examination of aspects that have not been thoroughly investigated 
to date, such as the reasons why target doses were not reached. 
 
In summary, after taking into consideration justified reasons for not prescribing drugs to patients with 
low EF, compliance with the guidelines was excellent in Spain. Simple estimation of the percentage of 
patients treated is a poor quality indicator of HF care. The focus should be changed from emphasis on the 
indications for treatments to the introduction of measures that will improve the attainment of optimal 
doses for each patient (taking into account the maximum tolerated dose according to clinical, 
hemodynamic, and/or toxicity-related factors). The continuous updating of the registry makes it a 
magnificent instrument for monitoring HF treatment in Spain and enables comparison with the situation 
in the rest of Europe in order to identify strengths and weaknesses
17
 and design improvements where 
necessary. 
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Appendix. List of Spanish Centers and the Investigators, by Provinces 
A Coruña 
Complexo Hospitalario Universitario de A Coruña 
e Instituto de Investigación Biomédica de A 
Coruña, A Coruña 
Eduardo Barge-Caballero, Paula Blanco-Canosa, Marisa Crespo-Leiro (PI), 
Zulaika Grille-Cancela, Raquel Marzoa-Rivas, Maria J. Paniagua-Martin 
Hospital Clínico Universitario, Santiago de 
Compostela 
Inés Gómez, Maria Moure, Ana Seoane, Alfonso Varela-Román (PI) 
Albacete 
Complejo Hospitalario Universitario de Albacete, 
Albacete 
Manuel José Fernández-Anguita, Juan Carlos Gallego-Page (PI), Francisco 
M. Salmerón-Martínez 
Alicante 
Hospital Universitario de San Juan, San Juan de 
Alicante 
Vicente Bertomeu, Amin ElAmrani, Ruben Martínez-Abellán, Irene Mateo, 
Juan Quiles (PI), Jose Angel Rodríguez-Ortega, Ricardo Valero 
Asturias 
Hospital Universitario Central de Asturias, Oviedo Beatriz Díaz-Molina (PI), Elena Díaz-Velasco, José Luis Lambert-Rodríguez 
Barcelona 
Hospital de Sabadell, Sabadell Francisco Epelde-Gonzalo (PI), Josefina Orus 
Hospital Universitario Germans Trias i Pujol, 
Badalona 
Antoni Bayes-Genis (PI) 
Hospital de la Santa Creu i Sant Pau, Barcelona Lola García-Cosío, Ana Méndez, Sonia Mirabet, Eulàlia Roig (PI) 
Hospital Universistari de Bellvitge, L’Hospitalet de 
Llobregat 
Alberto Garay, Jose González-Costello (PI), Valentina León, Guillem 
Muntané 
Granada 
Hospital Universitario Virgen de las Nieves, 
Granada 
Vicente Alcade-Martínez, Marta Fernández-Álvarez, Silvia López-Fernández 
(PI), Monserrat Puga-Martínez, Ricardo Rivera-López, Jose Luis Serrano-
Martínez 
Balearic Islands 
Hospital Manacor, Mallorca Bernardo García-de la Villa, Ana Sahuquillo (PI) 
  
  
Madrid 
Hospital de Cantoblanco, Madrid 
Andrea Araujo, Almudena Castro-Conde, Regina Dalmau González-Gallarza 
(PI), Angel Manuel Iniesta-Manjavacas, Sandra Ofelia Rosillo, Oscar 
Salvador-Montanés 
Hospital Universitario Puerta de Hierro, 
Majadahonda 
Luis Alonso-Pulpón, Ana Briceno, Marta Cobo-Marcos, Pablo García-Pavia, 
Manuel Gómez-Bueno, Ariadna González-Segovia, Inés Sayago, Javier 
Segovia-Cubero (PI), Teresa Soria 
Hospital Universitario 12 de Octubre, Madrid 
Elvira Barrios Garrido-Lestache, Juan F. Delgado-Jiménez (PI), Pilar 
Escribano-Subías, Miguel Angel Gómez-Sánchez, Maria José Ruiz-Cano, 
Maria Vicente-Hernández 
Málaga 
Hospital Costa del Sol, Marbella Rafael Bravo-Marqués, Francisco Torres-Calvo (PI) 
Hospital Regional Universitario Carlos Haya, 
Málaga 
Manuel de Mora-Martín (PI), Ana García-Bellón, Ana González-González, 
Jose Maria Pérez-Ruiz, Beatriz Pérez-Villardón 
Hospital Universitario Virgen de la Victoria, 
Málaga 
Jose Manuel García-Pinilla (PI) 
Murcia 
Hospital Universitario Virgen de la Arrixaca, El 
Palmar 
Iris P. Garrido-Bravo, María Rosario Gracia-Rodenas, Domingo A. Pascual-
Figal (PI), Francisco Pastor-Pérez, Maria Teresa Pérez-Martínez 
Pontevedra 
Hospital Povisa, Vigo Juan Carlos Arias (PI) 
Santa Cruz de Tenerife 
Hospital Universitario de Canarias, La Laguna 
Idaira Famara Hernández-Baldomero, Antonio Lara-Padrón (PI), Ignacio 
Laynez-Cerdena 
Seville 
Hospital Universitario Virgen Macarena, Seville Carla Fernández-Vivancos (PI) 
Tarragona 
Hospital de Tortosa Verge de la Cinta, Tortosa David Bierge-Valero (PI) 
Valencia 
Consorcio Hospital General Universitario de 
Valencia, Valencia 
Lorenzo Fácila-Rubio, David García-Escriva, Pilar García-González, Angel 
Pellicer-Cabo, Jose Pérez-Silvestre, Francisco Ridocci-Soriano (PI) 
Hospital Universitari i Politècnic La Fe, Valencia Luis Almenar-Bonet (PI), Elena Marqués-Sule, Ignacio J. Sánchez-Lázaro 
Valladolid 
Hospital Clínico Universitario de Valladolid, 
Valladolid 
Luis de la Fuente-Galán (PI), Javier López-Díaz, Amada Recio-Platero 
Vizcaya 
Hospital San Eloy, Barakaldo Javier Andrés (PI) 
Zaragoza 
Hospital Universitario Miguel Servet, Zaragoza 
Carmen Aured-Guallar, Teresa Blasco-Peiró, Ana Portolés-Ocampo, Ester 
Sánchez-Insa, Marisa Sanz Julve (PI) 
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